Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement
Makes an upfront payment of US$10m to BioNTech
Genmab of Denmark has entered into a technology agreement with German biotechnology company BioNTech to jointly research, develop and commercialise multiple bispecific antibodies for cancer immunotherapy.
The agreement will use technologies from both companies including BioNTech’s immunomodulatory antibodies and Genmab’s DuoBody technology platform.
Genmab will pay an upfront fee of US$10m to BioNTech and additional potential near-term payments of up to $5m if certain BioNTech assets are developed further.